This article is more than 5 years old. Information may no longer be current.

Study links anti-VEGF use with elevated IOP

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — Anti-VEGF treatment for wet age-related macular degeneration was found to increase IOP in some patients, according to study data released here at the joint meeting of the American Academy of Ophthalmology and Pan-American Association of Ophthalmology.

Researchers at Yale University School of Medicine found that of 116 AMD patients treated with Avastin (bevacizumab, Genentech) and/or Lucentis (ranibizumab, Genentech), four patients (3.45%) had a significant, sustained increase in IOP.

"To our knowledge, ours is the first study to document persistent ocular hypertension following intravitreal bevacizumab injections in patients with no personal or family history of glaucoma or ocular hypertension," Ron A. Adelman, MD, MPH, said. "We found that sustained, high IOP may occur after only one anti-VEGF injection, but more typically after multiple injections. Patients' [ocular hypertension] may continue over several AMD treatments and may require IOP-lowering therapy."